For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying ... providing a background level of blood glucose control ...

Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...

In a report released today, Jo Walton from UBS maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Novo Nordisk (NVO) has released an update. Pick the best stocks and maximize your portfolio: Novo Nordisk, a leading healthcare company, has launched a share repurchase program with a target of ...

Few companies have broken into the public’s consciousness as thoroughly as Novo Nordisk has over the past couple of years. Its Wegovy weight-loss drug and Ozempic diabetes treatment are so ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabetes ...

Pre-Market: 4:40:34 a.m. EST ...